|
WO2018181135A1
|
|
Method for producing learning effectiveness-improving agent and learning effectiveness-improving food product composition, and technology pertaining thereto
|
|
TW201842927A
|
|
Method for producing anxiolytic drug and anxiolytic food product composition, and technology pertaining thereto
|
|
TW201842926A
|
|
Autonomic nerve regulator, food composition for autonomic nerve regulation, and related technology
|
|
JP2019123670A
|
|
BDNF-TrkB SIGNALING SYSTEM ACTIVATOR AND BDNF-TrkB SIGNALING SYSTEM ACTIVATING FOOD COMPOSITION
|
|
JP2017007974A
|
|
Cardiac function regulatory agent
|
|
JP2016079116A
|
|
Homocysteine level inhibitor
|
|
SG10201706242QA
|
|
Use of cell wall disrupted product of chlorella for reducing serum resistin level
|
|
JP2013014618A
|
|
Gaba pentine receptor binding inhibitor
|
|
JP2013121941A
|
|
Sympathetic nerve inhibitor, and food and drink composition for inhibiting sympathetic nerve
|
|
JP2008231072A
|
|
Enzyme activity inhibitor and receptor binding inhibitor
|
|
JP2007277099A
|
|
Hyperinsulinemia-improving agent
|
|
JP2007269728A
|
|
Food and drink composition
|
|
JP2006213613A
|
|
Hepatopathy inhibitor
|
|
JP2006069994A
|
|
Orally administered medicine for inhibiting carcinogenesis
|
|
JP2005089323A
|
|
Matrix metalloprotease inhibitor
|
|
JP2005089325A
|
|
Cytokine release inhibitor
|
|
JP2005089322A
|
|
Tyrosine phosphatase inhibitor
|
|
JP2005089321A
|
|
Phorbol ester receptor bonding inhibitor
|
|
JP2005089326A
|
|
B/t cell proliferation inhibitor
|
|
JP2005089324A
|
|
Caspase inhibitor
|
